Characteristic | Value (N = 80) |
---|---|
Median age, years (range) | 60.0 (34–84) |
Sex, n (%) | |
Male | 63 (79) |
Female | 17 (21) |
Race | |
White, n (%) | 72 (90) |
Black, n (%) | 1 (1) |
Asian, n (%) | 1 (1) |
Other | 3 (4) |
Information missing | 3 (4) |
Ethnicity | |
Hispanic or Latino | 5 (6) |
Not Hispanic or Latino | 67 (84) |
Not stated | 2 (3) |
Unknown | 6 (8) |
Variant HCL, n (%) | 3 (4) |
Splenectomy, n (%) | 5 (6) |
Number of prior systemic therapies, median (range) | 3 (2–11) |
> 3 prior lines, n (%) | 39 (49) |
Baseline hemoglobin, g/dL, median (range) | 11.1 (6.5–16.3) |
Baseline neutrophil count, × 103/µL, median (range) | 0.81 (0.1–6.2) |
Baseline platelet count, × 103/µL, median (range) | 68.0 (6.0–350.0) |
Prior cancer therapy, n (%) | |
PNA | 80 (100) |
Rituximab | 60 (75) |
BRAF inhibitor | 14 (18) |
Interferon-α | 20 (25) |
Other | 8 (10) |
Unfit for PNA re-treatment, n (%) | 30 (38) |
At risk of infectiona | 20 (25) |
Active infectionb | 19 (24) |
Patients refractory to PNA,c n (%) | 39 (49) |
PNA monotherapyd | 29 (36) |
PNA + rituximabe | 15 (19) |